Rivaroxaban combined with folic acid in treatment of 20 cases of cyanotic vascular disease
Objective To investigate the clinical effect of rivaroxaban combined with folic acid in the treatment of live-doid vasculopathy(LV).Methods Totally 20 LV patients admitted to the Kaifeng People's Hospital from March 2022 to June 2023 were selected.All patients were given orally rivaroxaban 10 mg/d and folic acid tablets 5 mg/d.The skin lesion symptoms and pain degree,thromboelastogram index,vasculo-related factors,inflammatory factors and erythro-cyte folic acid levels before treatment,4 weeks and 8 weeks of treatment were compared.The adverse reactions and re-currence were observed during treatment.Results The scores of erythema,ulcer and pain in LV patients before treat-ment were(2.34±0.58),(2.41±0.54)and(7.86±1.68),which decreased to(1.53±0.46),(1.48±0.38)and(4.57±1.32)after 4 weeks of treatment.After 8 weeks of treatment,the results decreased to(1.05±0.71)points,(0.88±0.28)points and(0.75±0.53)points,and the differences were statistically significant at different time points(P＜0.05).The R values and K values of LV patients before treatment were(4.97±1.44)and(1.95±0.21),which increased to(7.18±1.52)and(2.36±0.18)after4 weeks of treatment,and increased to(7.37±1.28)and(2.49±0.27)after 8 weeks of treatment.After 4 weeks of treatment and 8 weeks of treatment,the difference was statistically signifi-cant(P＜0.05).The levels of vascular endothelial growth factor and nitric oxide in LV patients were(947.66±237.84)ng/L and(44.96±8.47)μmol/L before treatment,and increased to(1 636.54±295.85)ng/L and(65.72±9.71)µmol/L after 4 weeks of treatment.After 8 weeks of treatment,the levels increased to(2374.95±363.78)ng/L and(83.75±10.82)μmol/L.The levels of soluble vascular endothelial growth factor receptor-1 and endothelin-1 were(12 626.95±595.06)ng/L and(105.72±9.74)ng/L before treatment,and decreased to(9 874.58±527.92)ng/L and(71.63±10.35)ng/L after4 weeks of treatment.After 8 weeks of treatment,the lev-els decreased to(8 479.60±462.84)ng/L and(52.86±8.72)ng/L,and the differences were statistically significant at different time points(P＜0.05).The levels of interleukin-6 and C-reactive protein in LV patients were(82.83±5.94)and ng/L(42.86±5.92)mg/L before treatment,and decreased to(56.92±6.69)ng/L and(27.83±7.28)mg/L after 4 weeks of treatment.After 8 weeks of treatment,the levels decreased to(32.55±4.96)ng/L and(11.74±4.28)mg/L,and the differences were statistically significant at different time points(P＜0.05).The eryth-rocyte folate level in LV patients was(426.92±37.82)mg/L before treatment,increased to(615.25±43.37)mg/L after 4 weeks of treatment,and increased to(773.72±46.82)mg/L after 8 weeks of treatment,with statistical signifi-cance at different time points(P＜0.05).Conclusion Rivaroxaban combined with folic acid in the treatment of LV can effectively improve the symptoms of blood damage and relieve pain,and its mechanism may be related to improving coag-ulation function,inhibiting inflammatory response and increasing the level of folic acid in red blood cells.
RivaroxabanFolic acidLivedoid vasculopathyCoagulation function
NETL
NSTL
万方数据
